|
Tissue Cytokine Levels and Histopathology Following Liposomal Amphotericin B (LA) or Caspofungin (C) Treatment of Echinocandin Resistant (ER) or Sensitive (ES) Candida glabrata (Cg) Infection (click for details) |
|
|
|
Posaconazole Prophylaxis in Experimental Azole-resistant Invasive Pulmonary Aspergillosis (click for details) |
|
|
|
Comparison of CLSI and EUCAST Antifungal Susceptibility Profile with Therapeutic Outcome in HIV-positive Cryptococcosis Patients Due to Cryptococcus neoformans var. grubii in India (click for details) |
|
|
|
Variability of PKPD of Micafungin (MF) in Critically Ill Patients (CIP) (click for details) |
|
|
|
Epidemiology of Candidemia in a Spanish Tertiary Hospital: Identification and Molecular Mechanisms of Resistance (click for details) |
|
|
|
In vitro Studies of Exserohilum rostratum with Antifungal Drugs and Methylprednisolone (click for details) |
|
|
|
Impact of Candida species on the Isavuconazole (ISA) Pharmacodynamic (PD) Target in an in vivo Neutropenic Murine Model of Invasive Candidiasis (IC) (click for details) |
|
|
|
Conventional amphotericin B (AMB) activity against Aspergillus species in an in vitro pharmacokinetic (PK)-pharmacodynamic(PD) model (click for details) |
|
|
|
Disseminated Histoplasmosis in Costa Rica and the Use of Amphotericin B deoxycholate and Fluconazole as First Line of Theraphy (click for details) |
|
|
|
Safety, Tolerability, and Pharmacokinetics of Posaconazole Oral Suspension in Neutropenic Children (click for details) |
|
|
